Lung Adenocarcinoma

An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

Lung adenocarcinoma cell lines (H3122: EML4-ALK E13:A20, HCC78: SLC34A2-ROS1, H1993: MET amplification, and H596: MET exon 14 skipping) with putative crizotinib-sensitive genotypes were analyzed with … (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

This study contained 230 patients presenting with untreated lung adenocarcinoma. Tumor and matched normal material were analyzed via whole-exome sequencing. It was shown that ~62% of samples contained… (full text at CIViC)

PMID 25079552 · 2014, Nature · Open in CIViC

69 patients with lung adenocarcinoma from Beth Israel Deaconess Medical Center had their cancers submitted for genomic profiling to identify crizotinib-sensitive genomic events. There were 7 cases tha… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring MET D1028H mutation, a partial response to crizotinib treatment was reported with continued response for at least 6 months. Prior to crizotinib treatment, th… (full text at CIViC)

PMID 25898962 · Waqar et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010H mutation, stable disease to crizotinib monotherapy was reported. The patient was treated with crizotinib for 4 months; treatment was ongoing at … (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC

A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+.

PMID 25971938 · Frampton et al., 2015 · Open in CIViC

A 65-year old female (non-smoker) presented with right leg pain and edema. Percutaneous needle biopsy was performed on a mass-like lesion that appeared in a chest x-ray and revealed moderately differe…

A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC)

PMID 30600919 · Baba et al., 2019 · Open in CIViC

A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC)

PMID 30600919 · Baba et al., 2019 · Open in CIViC

A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC)

PMID 34994615 · Pruis et al., 2021 · Open in CIViC

A 67-year old Asian female (non-smoker) diagnosed with stage IV metastatic lung adenocarcinoma and also presented with superior vena cava syndrome and weight loss. Ultrasound-guided biopsy of lymph no… (full text at CIViC)

PMID 27666659 · Ou et al., 2017 · Open in CIViC

A 71-year old male (non-smoker) was diagnosed with stage IV lung adenocarcinoma. Genomic profiling of a lung cavity showed MET exon 14 skipping mutation and the patient began crizotinib therapy. Treat… (full text at CIViC)

PMID 28629543 · Schrock et al., 2017 · Open in CIViC

A 69-year old male (50 year history of smoking) was diagnosed with stage IIIC lung adenocarcinoma after a 13.2 x 8.8 x 9 cm mass with multiple lymph node metastases were found in a CT scan. Next-gener… (full text at CIViC)

PMID 29381967 · Tan et al., 2017 · Open in CIViC

A 72-year old man (non-smoker) was diagnosed with lung adenocarcinoma and developed multiple recurring brain and lung metastases. Systemic chemotherapy was administered, and genomic analysis of the su… (full text at CIViC)

PMID 34695875 · Kunimasa et al., 2021 · Open in CIViC

In one patient with metastastic lung adenocarcinoma harboring a c-Cbl binding site alteration (Y1021H) deomonstrated radiological response to crizotinib and a PFS of 10.6 months.

PMID 31809977 · Wiesweg et al., 2020 · Open in CIViC

A 61-year old female (non-smoker) was diagnosed with stage IIIb adenocarcinoma of the left lung. Next-generation sequencing of the peripheral blood revealed MET Y1003S mutation. The patient was treate… (full text at CIViC)

PMID 30885356 · Miao et al., 2019 · Open in CIViC

In a retrospective cohort of metastatic lung adenocarcinoma from the BATTLE-2 trial (n = 72), patients with CDKN2A and MTAP co-underexpression tumors (n = 26; representative for 9p21 loss) demonstrate… (full text at CIViC)

PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC

25 tumors from individuals with lung adca who have <= 10 pack-year smoking history underwent whole exome sequencing and RNA-seq. 5 tumors did not identify an established oncogenic driver. In one (tumo… (full text at CIViC)

PMID 35247929 · Hunihan et al., 2022 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

HCC827 cell lines harboring activated PI3K (HCC827 p110α E545K cells) were more resistant to gefitinib in vitro (IC50, 1 μM) compared with those harboring GFP alone (IC50, 0.01 μM). The presence of p1… (full text at CIViC)

PMID 16906227 · Engelman et al., 2006 · Open in CIViC

48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed… (full text at CIViC)

PMID 27304188 · Belchis et al., 2016 · Open in CIViC

Lung adenocarcinoma cell lines with MET exon 14 skipping mutation and PIK3CA mutation (H596) were tested with GDC0941 (pictilisib) alone and with crizotinib. Analysis shows a statistically significant… (full text at CIViC)

PMID 26215952 · Liu et al., 2016 · Open in CIViC

Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha … (full text at CIViC)

PMID 19029981 · Engelman et al., 2008 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC